Journal of Clinical Oncology, Vol 1, 477-482, Copyright © 1983 by American Society of Clinical Oncology
Weekly doxorubicin in endocrine-refractory carcinoma of the prostate
FM Torti, D Aston, BL Lum, M Kohler, R Williams, JT Spaulding, L Shortliffe and FS Freiha
Twenty-five patients with endocrine-refractory prostatic carcinoma were
treated with doxorubicin, 20 mg/m2 given weekly. All patients had prior
hormonal therapy (68% had two or more prior hormonal maneuvers), and 21
(84%) had prior therapeutic or palliative irradiation. Median Karnofsky
performance status at the time of entry was 70. Hemoglobin was less than
12.0 g/dL in 15 patients. Bidimensional tumors were present in 12 patients
in 19 disease sites; four of the 12 patients (33%) responded in eight of
the 19 sites (42%); and three of eight patients had a 75% decrease in
prostatic nodule size. Ten of 20 evaluable patients had an improvement of
20% or greater in Karnofsky performance status and 67% (14 of 21) had
marked improvement in pain. A greater than 50% reduction or normalization
of acid phosphatase occurred in 19% and of alkaline phosphatase in 53%. The
overall response rate by National Prostatic Cancer Project criteria was
84%. Gastrointestinal toxicity and alopecia were minimal and
myelosuppression was not life threatening in any patient.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Facebook 
Reddit 
Technorati 
Twitter What's this?
